TipRanks (Wed, 18-Mar 8:50 AM ET)
TipRanks (Tue, 17-Mar 11:10 AM ET)
Clene Secures Third-Year NIH Subaward for ALS Program
TipRanks (Tue, 17-Mar 6:38 AM ET)
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
Globe Newswire (Thu, 12-Mar 8:00 AM ET)
Presenting on Emerging Growth Conference 90 Day 2 on February 26; Register to live stream
Globe Newswire (Wed, 25-Feb 7:00 AM ET)
Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8 2026 Catalysts
Globe Newswire (Tue, 24-Feb 8:00 AM ET)
Presenting on Emerging Growth Conference 90 Day 1 on February 25; Register to live stream
Globe Newswire (Tue, 24-Feb 7:00 AM ET)
Clene to Present at the Emerging Growth Conference
Globe Newswire (Thu, 19-Feb 8:30 AM ET)
Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream
Globe Newswire (Wed, 21-Jan 7:00 AM ET)
Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
Globe Newswire (Tue, 20-Jan 7:00 AM ET)
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Clene trades on the NASDAQ stock market under the symbol CLNN.
As of March 20, 2026, CLNN stock price declined to $5.32 with 150,948 million shares trading.
CLNN has a beta of 2.10, meaning it tends to be more sensitive to market movements. CLNN has a correlation of 0.07 to the broad based SPY ETF.
CLNN has a market cap of $62.72 million. This is considered a Micro Cap stock.
Last quarter Clene reported $77,000 in Revenue and -$.88 earnings per share. This beat revenue expectation by $48,500 and missed earnings estimates by -$.33.
In the last 3 years, CLNN traded as high as $25.40 and as low as $2.28.
The top ETF exchange traded funds that CLNN belongs to (by Net Assets): VTI, VXF.
CLNN has outperformed the market in the last year with a price return of +23.5% while the SPY ETF gained +15.6%. However, in the short term, CLNN had mixed performance relative to the market. It has underperformed in the last 3 months, returning -20.3% vs -4.7% return in SPY. But in the last 2 weeks, CLNN shares have fared better than the market returning +0.5% compared to SPY -4.8%.
CLNN support price is $5.49 and resistance is $6.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLNN shares will trade within this expected range on the day.